Medical/Pharmaceuticals
RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China
YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially...
2024-10-29 12:00
2435
The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris
PARIS, Oct. 29, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the Integratio...
2024-10-29 11:01
2079
GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies
YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy (GA...
2024-10-29 09:13
2518
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-10-29 07:57
3139
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while d...
2024-10-29 06:32
3959
KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I
Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to...
2024-10-29 05:42
1663
Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth
MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Alimetry
2024-10-29 05:08
1970
$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT
CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY
TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION
BOULDER, Colo. , Oct. 28, 2024 /PRNewswire/ -- Tessara Therapeutics
2024-10-29 02:00
2321
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year * Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year * Net Profit Attributable to the Owners o...
2024-10-28 19:03
2867
I-Mab to Participate at the Truist Securities BioPharma Symposium
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meet...
2024-10-28 19:00
1619
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expressio...
2024-10-28 17:00
1944
Lilly's Mounjaro® (tirzepatide) Approved in Hong Kong in KwikPen® Presentation for Chronic Weight Management and Type 2 Diabetes, Offering a New Option for the Treatment of Obesity, Overweight and Type 2 Diabetes
* Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 * Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials6-12 * Mounjaro represents a new class of obesity and diabetes medicines and is expected to be ava...
2024-10-28 15:12
3338
/C O R R E C T I O N -- Seegene Inc./
In the news release, Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative, issued 24-Oct-2024 by Seegene Inc. over PR Newswire, we are advised by the company that the second photo and its caption should be removed as origina...
2024-10-28 12:50
5296
DKSH and FrontierView Publish Whitepaper on Southeast Asia as a Growth Accelerator for Global Healthcare Firms
DKSH and FrontierView, a business intelligence and advisory firm, published a whitepaper providing an in-depth assessment of the healthcare status of the Southeast Asia (SEA) region. The research collated in DKSH's whitepaper provides a comprehensive analysis of the regional healthcare landscape,...
2024-10-28 09:00
4871
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Today at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) c...
2024-10-28 02:56
2043
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for th...
2024-10-26 01:24
4737
KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)
SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Fo...
2024-10-26 00:33
2379
WOORIEN launches 'MyVet CT Plus': Advanced Veterinary imaging Solution
* Lowering CT barriers and improving diagnostic quality * Spiral-Linear Technology with Enhanced Power * Various and Wide FOV with Reduced Scan Time HWASEONG, South Korea, Oct. 25, 2024 /PRNewswire/ -- WOORIEN Co., Ltd, a company specializing in veterinary imaging equipment and solutions, pr...
2024-10-25 21:00
3324
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...
2024-10-25 20:30
2799
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 inAustralia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycoba...
2024-10-25 19:29
2348
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 313 media titles]
2026-02-03 11:00
Mastercard Launches Portfolio of Fleet Solutions in Asia Pacific
[Picked up by 310 media titles]
2026-02-04 09:00Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00